Early Experience with MRI-Ultrasound Fusion-Guided Prostate Biopsy in Our Institution
-
- YOZA Naoto
- The Department of Urology, St Marianna University School of Medicine
-
- NAKAZAWA Ryuto
- The Department of Urology, St Marianna University School of Medicine
-
- NISHI Tomohiro
- The Department of Urology, St Marianna University School of Medicine
-
- TSUKADA Hikaru
- The Department of Urology, St Marianna University School of Medicine
-
- SHIRAI Daisuke
- The Department of Urology, St Marianna University School of Medicine
-
- ADACHI Hiroyuki
- The Department of Urology, St Marianna University School of Medicine
-
- YAMADA Ryuji
- The Department of Urology, St Marianna University School of Medicine
-
- MATSUMURA Kaori
- The Department of Urology, St Marianna University School of Medicine
-
- IWATA Teppei
- The Department of Urology, St Marianna University School of Medicine
-
- USUBA Wataru
- The Department of Urology, St Marianna University School of Medicine
-
- AIDA Kouichirou
- The Department of Urology, St Marianna University School of Medicine
-
- HAYAKAWA Nozomi
- The Department of Urology, St Marianna University School of Medicine
-
- SASAKI Hideo
- The Department of Urology, St Marianna University School of Medicine
-
- KIKUCHI Eiji
- The Department of Urology, St Marianna University School of Medicine
Bibliographic Information
- Other Title
-
- MRI-US融合画像ガイド下前立腺生検における癌検出率の検討
- MRI-US ユウゴウ ガゾウ ガイド カ ゼンリツセンセイケン ニ オケル ガン ケンシュツリツ ノ ケントウ
Search this article
Abstract
A total of 100 patients were retrospectively analyzed with magnetic resonance imaging-ultrasonography (MRI-US) fusion biopsy(KOELIS, TRINITY®) at our institution between October 2019 and May 2020. The median patient age was 71 years, median prostate specific antigen (PSA) level was 7.4 ng/ml, and median PSA-density was 0.183 mg/ml. Sixty-one of the patients were positive for cancer ; 14 of them were positive by targeted biopsy only, 9 were positive by systematic biopsy only, and 38 were positive by both. Clinically significant prostate cancer (CPSC ; Gleason Score ≥3+4 and % core ≥50%) was detected by target biopsies in 46 patients and by systematic biopsies in 33 patients. The positive core detection rate for CSPC was 32.5% for targeted biopsies and 7.0% for systematic biopsies(P<0.0001), with a significantly higher rate for targeted biopsies. These results indicate that in MRI-US fusion biopsy, targeted biopsy has a higher detection rate for cancer and a significantly higher detection rate for clinically significant prostate cancer compared with systematic biopsy.
Journal
-
- 泌尿器科紀要
-
泌尿器科紀要 68 (9), 291-294, 2022-09-30
泌尿器科紀要刊行会
- Tweet
Details 詳細情報について
-
- CRID
- 1390575185898313472
-
- NII Book ID
- AN00208315
-
- HANDLE
- 2433/276607
-
- NDL BIB ID
- 032401829
-
- ISSN
- 00181994
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- IRDB
- NDL
-
- Abstract License Flag
- Allowed